(Albany, US) September 10, 2026- DelveInsight’s “Shingles Pipeline Insight, 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Shingles pipeline landscape. It covers the Shingles pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Shingles pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the Shingles Treatment Landscape @ https://www.delveinsight.com/report-store/shingles-pipeline-insight
Key Takeaways from the Shingles Pipeline Report
DelveInsight’s Shingles pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Shingles treatment.
The leading Shingles Companies include Curevo Vaccine, Jiangsu Recbio Technology, Zhuhai Trinomab Pharmaceutical, Nobelpharma, Dynavax Technologies Corporation, Jiangsu Rec-Biotechnology, Moderna, Amytrx Therapeutics, and others.
Promising Shingles Pipeline Therapies such as Amezosvatein (CRV-101), REC610, and others.
The companies which have their Shingles drug candidates in the most advanced stage, i.e. Phase II, include Curevo Vaccine.
Gain in-depth knowledge of key Shingles clinical trials, emerging drugs, and market opportunities @ Shingles Clinical Trials Assessment
Shingles Overview
Shingles, also known as herpes zoster, is a viral disease caused by the reactivation of the varicella-zoster virus, which remains dormant in the sensory ganglia after an initial chickenpox infection. Typically affecting adults and the elderly, shingles arises when the immune system can no longer keep the virus in check, and its incidence is strongly correlated with immune status — those maintaining robust immunity rarely develop the condition. Shingles is not merely a benign infection; it can present in various forms and often leads to complications such as postherpetic neuralgia, a persistent and severe pain that continues even after the rash has resolved, making the condition especially important to understand and manage for those with weakened immune systems.
Shingles typically begins with a prodromal phase characterized by pain, itching, or tingling in a localized area, often accompanied by fever, headache, and malaise, followed by a painful, blistering rash that usually develops on one side of the body or face along the path of a sensory nerve. The rash starts as red patches that evolve into fluid-filled blisters, which eventually crust over and heal within two to four weeks, though many individuals go on to experience postherpetic neuralgia, severe nerve pain that can persist long after the visible symptoms disappear. Diagnosis relies on clinical examination of the characteristic burning pain, rash morphology, and distribution, supported by tests such as the Tzanck smear, direct fluorescent antibody (DFA) testing, and polymerase chain reaction (PCR), with real-time PCR preferred for its high sensitivity and rapid results; differential diagnosis distinguishes shingles from conditions such as herpes simplex, contact dermatitis, and dental infections.
Treatment of herpes zoster takes a multifaceted approach aimed at hastening lesion resolution, reducing acute pain, and preventing complications like postherpetic neuralgia. Antiviral medications such as acyclovir, valacyclovir, and famciclovir combat the virus and are most effective when started early, while topical antibiotic creams like mupirocin or soframycin help prevent secondary bacterial infections. Pain management includes analgesics and, in severe cases, opioid medications, along with topical lidocaine and nerve blocks, and for postherpetic neuralgia — particularly in elderly patients — topical treatments such as capsaicin and Emla cream are recommended once lesions have crusted.
Shingles Emerging Drugs Profile
Amezosvatein (CRV-101): Curevo Vaccine Amezosvatein is an investigational non-mRNA adjuvanted sub-unit vaccine for the prevention of shingles (herpes zoster) in adults and chickenpox (varicella) in children. As a sub-unit vaccine, it does not contain virus components and cannot cause infection; it targets glycoprotein E (gE) on the varicella virus, a target proven by others to be safe and effective for shingles prevention. The adjuvant component was specifically engineered to produce an optimal immune response while improving tolerability. Currently, the drug is in the Phase II stage of its clinical trial for the treatment of shingles.
REC610: Jiangsu Recbio Technology REC610 is a novel adjuvanted recombinant shingles vaccine developed by Jiangsu Recbio Technology, which received a clinical trial approval notice from the National Medical Products Administration (NMPA) in October 2023. The vaccine demonstrated a positive safety profile in a Phase I trial in the Philippines, where it was compared to GSK’s Shingrix, showing a favorable safety and tolerability profile in healthy participants aged 40 and above after two doses, with no serious adverse events reported. REC610 induced strong gE-specific humoral and cellular immune responses that peaked at 30 days after the second vaccination. Currently, the drug is in the Phase I stage of its clinical trial for the treatment of shingles.
The Shingles Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Shingles, with aggregate therapies developed by each company.
It assesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage development for Shingles treatment.
Shingles Companies are involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.
Shingles drugs under development are categorized based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecule type.
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, mergers and acquisitions, and funding for future advancement of the Shingles market.
Uncover critical updates on therapeutic innovations and their potential impact on patients @ Shingles Unmet Needs
Shingles Companies
Curevo Vaccine, Jiangsu Recbio Technology, Zhuhai Trinomab Pharmaceutical, Nobelpharma, Dynavax Technologies Corporation, Jiangsu Rec-Biotechnology, Moderna, Amytrx Therapeutics, and others.
Shingles pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Shingles Products have been categorized under various Molecule types such as:
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Transform your understanding of the Shingles Pipeline! @ Shingles Market Drivers and Barriers, and Future Perspectives
Scope of the Shingles Pipeline Report
Coverage- Global
Shingles Companies- Curevo Vaccine, Jiangsu Recbio Technology, Zhuhai Trinomab Pharmaceutical, Nobelpharma, Dynavax Technologies Corporation, Jiangsu Rec-Biotechnology, Moderna, Amytrx Therapeutics and others.
Shingles Pipeline Therapies- Amezosvatein (CRV-101), REC610 and others.
Shingles Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Shingles Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Access the Full Shingles Pipeline Analysis Today! @ Shingles Drugs and Companies
Table of Contents
Introduction
Executive Summary
Shingles: Overview
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Shingles: DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I)
Preclinical and Discovery Stage Products
Inactive Products
Shingles Key Companies
Shingles Key Products
Shingles: Unmet Needs
Shingles: Market Drivers and Barriers
Shingles: Future Perspectives and Conclusion
Shingles Analyst Views
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kanishk KumarEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/shingles-pipeline-insight
